Open-Label Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral SCY-078 as an Emergency Use Treatment for Patients With Candidiasis, Including Candidemia, Caused by Candida Auris
Phase of Trial: Phase III
Latest Information Update: 26 Jun 2018
At a glance
- Drugs Ibrexafungerp (Primary)
- Indications Candidaemia; Candidiasis
- Focus Therapeutic Use
- Acronyms CARES
- Sponsors SCYNEXIS
- 04 Dec 2017 Status changed from planning to recruiting.
- 15 Nov 2017 New trial record
- 07 Nov 2017 According to a SCYNEXIS media release, patient enrollment is expected to commence in the fourth quarter of 2017.